Substituted indanyl sulfonamide compounds, their preparation and use as medicaments

Abstract

The present invention refers to new indanyl sulphonamide compounds with general formula (I), as well as to their preparation procedure, their application as medicine and the pharmaceuticals composition which they are made up of. The new compounds of formula (I) show affinity for 5-HT 6 receptors and are, therefore, effective for treating diseases mediated by these receptors.

1 . A substituted indanyl sulfonamide compound of general formula I, 
     
       
         
         
             
             
         
       
       wherein 
       R 1 , R 2 , R 3 , R 4 , independent from one another, each represent an hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; 
       R 5 , R 6 , R 7  and R 8 , independent from one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—H; —C(═)—R 10 ; —OR 11 ; —SR 12 ; —S(═O) 2 —N(R 14 )R 15 , —N(R 16 )—S(═O) 2 —R 17 ; —NH—R 18 ; —NR 19 R 20 ; F; Cl, Br; I; a linear or branched, saturated or unsaturated C 1-6  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NH—C(═O)—C 1-5 -alkyl, —N(C 1-5 -alkyl)-C(═O)—C 1-5 -alkyl, —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C 1-6  alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s); 
       with the condition that at least one of the substituents R 5 , R 6 , R 7  and R 8  represents a —S(═O) 2 —N(R 14 )R 15  or a —N(R 16 )—S(═O) 2 —R 17  radical; 
       A represents 
     
     
       
         
         
             
             
         
       
       which respectively means (Ia) and (Ib) type compounds: 
     
     
       
         
         
             
             
         
       
       wherein 
       n is 1, 2, 3 or 4 
       X represents NH, O or S 
       R 23  represents NH 2  or NH—NH 2  or otherwise R 23  together with X forms a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring with up to three heteroatoms selected from N, O or S 
       R 24  represents a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3    
       R 9  and R 9a , independent from one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; 
       or 
       R 9  and R 9a  together with the bridging nitrogen atoms form a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, oxo (═O), thioxo (═S), —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl and which may contain 1, 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as a ring member(s) 
       R 9b  represent a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3    
       R 10  to R 22 , independent from one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; a saturated or unsaturated 3 to 8-membered cycloaliphatic radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, oxo (═O), thioxo (═S), —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1,5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may optionally contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which may be bonded via a linear or branched C 1-6  alkylene group; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NH—C(═O)—C 1-5 -alkyl, —N(C 1-5 -alkyl)-C(═O)—C 1-5 -alkyl, —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C 1-6  alkylene, C 2-6  alkenylene or C 2-6  alkinylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s); 
       with the condition that when R 9  and R 9a  form a saturated, unsaturated or aromatic 3 to 9-membered heterocyclic ring optionally substituted, none of R 5 , R 6 , R 7  or R 8  represent —S(═O) 2 —N(R 14 )R 15    
       or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof 
       optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     
   
   
       2 . A substituted indanyl sulfonamide compound of general formula I, 
     
       
         
         
             
             
         
       
       wherein 
       R 1 , R 2 , R 3 , R 4 , independent from one another, each represent an hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; 
       R 5 , R 6 , R 7  and R 8 , independent from one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—H; —C(═O)—R 10 ; —OR 11 ; —SR 12 ; —S(═O) 2 —N(R 14 )R 15 , —N(R 16 )—S(═O) 2 —R 17 ; —NH—R 18 ; —NR 19 R 20 ; F; Cl, Br; I; a linear or branched, saturated or unsaturated C 1-6  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NH—C(═O)—C 1-5 -alkyl, —N(C 1-5 -alkyl)-C(═O)—C 1-5 -alkyl, —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C 1-6  alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s); 
       with the condition that at least one of the substituents R 5 , R 6 , R 7  and R 8  represents a —S(═O) 2 —N(R 14 )R 15  or a —N(R 16 )—S(═O) 2 —R 17  radical; 
       A represents 
     
     
       
         
         
             
             
         
       
       which respectively means (Ia) and (Ib) type compounds: 
     
     
       
         
         
             
             
         
       
       wherein 
       n is 1, 2, 3 or 4 
       X represents NH, O or S 
       R 23  represents NH 2  or NH—NH 2    
       R 24  represents a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3    
       R 9  and R 9a , independent from one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; 
       or 
       R 9  and R 9a  together with the bridging nitrogen atoms form a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, oxo (═O), thioxo (═S), —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 alkyl) 2 , —S(=O) 2 —C 1-5 alkyl, —S(═O) 2 -phenyl and which may contain 1, 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as a ring member(s) 
       R 9b  represent a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3    
       R 10  to R 22 , independent from one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; a saturated or unsaturated 3 to 8-membered cycloaliphatic radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, oxo (═O), thioxo (═S), —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may optionally contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which may be bonded via a linear or branched C 1-6  alkylene group; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NH—C(═O)—C 1-5 -alkyl, —N(C 1-5 -alkyl)-C(═O)—C 1-5 -alkyl, —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C 1-6  alkylene, C 2-6  alkenylene or C 2-6  alkinylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s); 
       with the condition that when R 9  and R 9a  form a saturated, unsaturated or aromatic 3 to 9-membered heterocyclic ring optionally substituted, none of R 5 , R 6 , R 7  or R 8  represent —S(═O) 2 —N(R 14 )R 15    
       or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof 
       optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     
   
   
       3 . A substituted indanyl sulfonamide compound of general formula I, 
     
       
         
         
             
             
         
       
       wherein 
       R 1 , R 2 , R 3 , R 4 , independent from one another, each represent an hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; 
       R 5 , R 6 , R 7  and R 8 , independent from one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—H; —C(═O)—R 10 ; —OR 11 ; —SR 12 ; —S(═O) 2 —N(R 14 )R 15 ; —N(R 16 )—S(═O) 2 —R 17 ; —NH—R 18 ; —NR 19 R 20 ; F; Cl, Br; I; a linear or branched, saturated or unsaturated C 1-6  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NH—C(═O)—C 1-5 -alkyl, —N(C 1-5 -alkyl)-C(═O)—C 1-5 -alkyl, —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C 1-6  alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s); 
       with the condition that at least one of the substituents R 5 , R 6 , R 7  and R 8  represents a —S(═O) 2 —N(R 14 )R 15  or a —N(R 16 )—S(═O) 2 —R 17  radical; 
       A represents 
     
     
       
         
         
             
             
         
       
       which respectively means (Ia) and (Ib) type compounds: 
     
     
       
         
         
             
             
         
       
       wherein 
       n is 1, 2, 3 or 4 
       X represents NH, O or S 
       R 23  represents NH 2  or NH—NH 2  or otherwise R 23  together with X forms a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring with up to three heteroatoms selected from N, O or S 
       R 24  represents a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3    
       R 9  and R 9a , independent from one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; 
       or 
       R 9  and R 9a  together with the bridging nitrogen atoms form a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, oxo (═O), thioxo (═S), —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl and which may contain 1, 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as a ring member(s) 
       R 9b  represent a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3    
       R 10  to R 22 , independent from one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; a saturated or unsaturated 3 to 8-membered cycloaliphatic radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, oxo (═O), thioxo (═S), —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may optionally contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which may be bonded via a linear or branched C 1-6  alkylene group; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NH—C(═O)—C 1-5 -alkyl, —N(C 1-5 -alkyl)-C(═O)—C 1-5 -alkyl, —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C 1-6  alkylene, C 2-6  alkenylene or C 2-6  alkinylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s); 
       with the condition that when R 9  and R 9a  form a saturated, unsaturated or aromatic 3 to 9-membered heterocyclic ring optionally substituted, R 6  does not represent —S(═O) 2 —N(R 14 )R 15    
       or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof, 
       optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     
   
   
       4 . A substituted indanyl sulfonamide compound of general formula I, 
     
       
         
         
             
             
         
       
       wherein 
       R 1 , R 2 , R 3 , R 4 , independent from one another, each represent an hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; 
       R 5 , R 6 , R 7  and R 8 , independent from one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—H; —C(═O)—R 10 ; —OR 11 ; —SR 12 ; —S(═O) 2 —N(R 14 )R 15 ; —N(R 16 )—S(═O) 2 —R 17 ; —NH—R 18 ; —NR 19 R 20 ; F; Cl, Br; I; a linear or branched, saturated or unsaturated C 1-6  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NH—C(═O)—C 1-5 -alkyl, —N(C 1-5 -alkyl)-C(═O)—C 1-5 -alkyl, —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C 1-6  alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s); 
       with the condition that at least one of the substituents R 5 , R 6 , R 7  and R 8  represents a —S(═O) 2 —N(R 14 )R 15  or a —N(R 16 )—S(═O) 2 —R 17  radical; 
       A represents 
     
     
       
         
         
             
             
         
       
       which respectively means (Ia) and (Ib) type compounds: 
     
     
       
         
         
             
             
         
       
       wherein 
       n is 1, 2, 3 or 4 
       X represents NH, O or S 
       R 23  represents NH 2  or NH—NH 2    
       R 24  represents a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3    
       R 9  and R 9a , independent from one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; 
       or 
       R 9  and R 9a  together with the bridging nitrogen atoms form a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, oxo (═O), thioxo (═S), —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O)—C 1-5 -alkyl, —S(═O) 2 -phenyl and which may contain 1, 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as a ring member(s) 
       R 9b  represent a hydrogen atom; or a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3    
       R 10  to R 22 , independent from one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated C 1-5  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; a saturated or unsaturated 3 to 8-membered cycloaliphatic radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, oxo (═O), thioxo (═S), —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may optionally contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which may be bonded via a linear or branched C 1-6  alkylene group; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 alkyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NH—C(═O)—C 1-5 -alkyl, —N(C 1-5 -alkyl)-C(═O)—C 1-5 -alkyl, —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C 1-6  alkylene, C 2-6  alkenylene or C 2-6  alkinylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s); 
       with the condition that when R 9  and R 9a  form a saturated, unsaturated or aromatic 3 to 9-membered heterocyclic ring optionally substituted, R 6  does not represent —S(═O) 2 —N(R 14 )R 15    
       or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof, 
       optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     
   
   
       5 . An indanyl sulfonamide compound according to any of  claims 1 - 4  wherein A represents: 
     
       
         
         
             
             
         
       
       which means (Ib) type compounds: 
     
     
       
         
         
             
             
         
       
     
   
   
       6 . An indanyl sulfonamide compound according to  claim 5  where X represents NH and R23 represents NH2 or otherwise R23 together with X forms a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring with up to three heteroatoms selected from N, O or S. 
   
   
       7 . An indanyl sulfonamide compound according to  claim 5  where X represents NH and R23 represents NH2. 
   
   
       8 . An indanyl sulfonamide compound according to any of  claims 1 - 4  wherein A represents 
     
       
         
         
             
             
         
       
       which means (Ia) type compounds: 
     
     
       
         
         
             
             
         
       
     
   
   
       9 . An indanyl sulfonamide compound according to  claim 8  where R 24  represents an hydrogen atom; R 9b  represents a saturated C 1-5  aliphatic radical or an hydrogen atom; and R 9  together with R 9a  represent a saturated or aromatic 3 to 9 membered heterocyclic ring or independently from one another each represent a hydrogen atom or a C 1-5  aliphatic radical. 
   
   
       10 . An indanyl sulfonamide compound according to any of  claims 1 - 4  wherein at least one of R 5 , R 6 , R 7  and R 8  represents a —N(R 16 )—S(═O) 2 —R 17  radical. 
   
   
       11 . An indanyl sulfonamide compound according to any of  claims 1 - 4  wherein at least one of R 5 , R 6 , R 7  and R 8  represents a —S(═O) 2 —N(R 14 )R 15  radical. 
   
   
       12 . An indanyl sulfonamide compound according to  claim 11  wherein at least one of R 14  and R 15  represents a 5- to 14-membered aryl or heteroaryl radical which may be substituted and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulphur as ring member(s). 
   
   
       13 . An indanyl sulfonamide compound according to  claim 12  wherein the 5- to 14-membered aryl or heteroaryl radical is substituted with Cl. 
   
   
       14 . An indanyl sulphonamide derivative according to  claims 1  to  4  wherein
 R 1 , R 2 , R 3  and R 4  represent an hydrogen atom or and C 1-5  aliphatic radical,   R 5 , R 6 , R 7  and R 8  represent an —S(═O) 2 —N(R 14 )R 15  radical or an —N(R 16 )—S(═O) 2 —R 17  radical, being R 14 , R 15 , R 16  and R 17  a 5- to 14-membered aryl or heteroaryl radical optionally substituted with Cl and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulphur as ring member(s)   A represents   
     
       
         
         
             
             
         
       
       which respectively means (Ia) and (Ib) type compounds: 
     
     
       
         
         
             
             
         
       
     
     wherein X represents NH and R 23  represents NH2 and where R 24  represents an hydrogen atom, R 9b  represents a hydrogen atom or a linear saturated C1-5 aliphatic radical and R9 together with R 9a  represent a saturated or aromatic 3 to 9 membered heterocyclic ring. 
   
   
       15 . An indanyl sulphonamide derivative according to  claims 1  to  4  wherein R 1 , R 2 , R 3  and R 4  represent an hydrogen atom or and C1-5 aliphatic radical,
 R 5 , R 6 , R 7  and R 8  represent an —S(═O) 2 —N(R 14 )R 15  radical or an —N(R 16 )—S(═O) 2 —R 17  radical, being R 14 , R 15 , R 16  and R 17  a 5- to 14-membered aryl or heteroaryl radical optionally substituted with Cl and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulphur as ring member(s)   A represents   
     
       
         
         
             
             
         
       
       which respectively means (Ia) and (Ib) type compounds: 
     
     
       
         
         
             
             
         
       
     
     wherein X represents NH and R 23  represents NH2 and where R 24  represents an hydrogen atom, or otherwise R 23  together with X forms a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring with up to three heteroatoms selected from N, O or S, R 9b  represents a hydrogen atom or a linear saturated C1-5 aliphatic radical and R9 together with R 9a  represent a saturated or aromatic 3 to 9 membered heterocyclic ring. 
   
   
       16 . An indanyl sulphonamide compound of general formula I according to  claim 1 , selected from:
 [1] N-[2-methyl-3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]naphtalene-2-sulfonamide   [2] N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]naphtalene-2-sulfonamide   [3] N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide   [4] N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonamide   [5] N-[3-(piperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonamide   [6] N-[1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-4-yl]-6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonamide   [7] N-[5-methoxy-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-4-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide   [8] 2-{6-[(2-naphthylsulfonyl)amino]-2,3-dihydro-1H-inden-1-ylidene}hydrazinecarboximidamide hydrochloride   [9] 2-(6-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide   [10] 2-(4-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide   [11] 2-(6-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-2-methyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide   [12] (+)-N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonamide   [13] (−)-N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonamide   [14] 6-chloro-N-[1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]imidazo[2,1b][1,3]thiazole-5-sulfonamide   [15] 6-chloro-N-[1,1-dimethyl-3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide   [16] 6-chloro-N-methyl-N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide   [17] 6-chloro-N-(3-{[2-(dimethylamino)ethyl](methyl)amino}-2,3-dihydro-1H-inden-5-yl)imidazo[2,1-b][1,3]thiazole-5-sulfonamide   [18] 6-chloro-N-(3-{[2-(dimethylamino)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)imidazo[2,1-b][1,3]thiazole-5-sulfonamide   [19] N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide   [20] 2-(6-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-3,3-dimethyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide hydrochloride   [21] 2-(5-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-2,3-dihydro-1H-inden-1-ylidene) hydrazinecarboximidamide hydrochloride   [22] 2-(6-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl](methyl)amino}-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide hydrochloride   [23] 2-(6-{[(4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-yl)sulfonyl]amino}-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide hydrochloride   [24] 6-chloro-N-[3-(4,5-dihydro-1H-imidazol-2-ylhydrazono)-2,3-dihydro-1H-inden-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide hydrochloride   [25] 6-chloro-N-[3-(4,5-dihydro-1H-imidazol-2-ylhydrazono)-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide hydrochloride   [26] N-[3-(4,5-dihydro-1H-imidazol-2-ylhydrazono)-2,3-dihydro-1H-inden-5-yl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide hydrochloride.   
   
   
       17 . An indanyl sulphonamide compound according to any of  claims 1 - 4  having the general formula (Ia): 
     
       
         
         
             
             
         
       
       where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 9a  R 9b , R 24  have the previously mentioned meanings and n=1, 2, 3 or 4. 
     
   
   
       18 . An indanyl sulphonamide compound according to any of  claims 1 - 4  having the general formula (Ib): 
     
       
         
         
             
             
         
       
       where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 23  and X have the previously mentioned meanings. 
     
   
   
       19 . Process for producing indanyl sulfonamide compounds of general formula (Ia): 
     
       
         
         
             
             
         
       
       where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 9a  R 9b , R 24  have the previously mentioned meanings and n=1, 2, 3 or 4 that comprises: 
       a) reacting an indanone of general formula (II): 
     
     
       
         
         
             
             
         
       
       where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7  and R 8  have the meaning given above, with a compound of formula (III): 
     
     
       
         
         
             
             
         
       
       where R 9 , R 9a  and R 9b  have the meaning given above in the presence of a Lewis acid at a temperature between 50° C. and 70° C., 
       b) reduction of the material resulting from step a) with a reducing agent in a suitable solvent at reflux. 
     
   
   
       20 . Process according to  claim 19  wherein the Lewis acid of step a) is titanium (IV) isopropoxide. 
   
   
       21 . Process according to  claim 19  wherein the reducing step b) is carried out with a solution of sodium borohydride in ethanol. 
   
   
       22 . Process for producing indanyl sulfonamide compounds of general formula (Ib): 
     
       
         
         
             
             
         
       
       wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 23  and X have the previously mentioned meanings, that comprises reacting an indanone of general formula (II): 
     
     
       
         
         
             
             
         
       
       wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7  and R 8  have the meaning given above, with a compound of formula (IV): 
     
     
       
         
         
             
             
         
       
       wherein R 23  and X have the meaning given above, in the presence of a suitable solvent in an acid medium at reflux. 
     
   
   
       23 . Process according to  claim 22  wherein reaction is carried out with methanol or acetonitrile as solvent and with hydrochloric acid as acid medium. 
   
   
       24 . An indanone of general formula (II): 
     
       
         
         
             
             
         
       
       wherein R 1 , R 2 , R 3 , R 4 , independent from one another, each represent an hydrogen atom; 
     
     or a linear or branched, saturated or unsaturated C1 — 5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ;
 R 5 , R 6 , R 7  and R 8 , independent from one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—H; —C(═O)—R 10 ; —OR 11 ; —SR 12 ; —S(═O) 2 —N(R 14 )R 15 , —N(R 16 )—S(═O) 2 —R 17 ; —NH—R 18 ; —NR 19 R 20 ; F; Cl, Br; I; a linear or branched, saturated or unsaturated C 1-6  aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN, —NH—CH 3  and —S—CH 3 ; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NH—C(═O)—C 1-5 -alkyl, —N(C 1-5 -alkyl)-C(═O)—C 1-5 -alkyl, —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C 1-6  alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s). 
 
   
   
       25 . An indanone of general formula (II) according to  claim 24  wherein least one of the substituents R 5 , R 6 , R 7  and R 8  represents a —S(═O) 2 —N(R 14 )R 15  or a —N(R 16 )—S(═O) 2 —R 17  radical. 
   
   
       26 - 28 . (canceled) 
   
   
       29 . A method of treatment of a disease or disorder mediated by 5HT 6  receptors comprising administering an indanyl sulphonamide compound according to any of  claims 1  to  4  to a patient in need thereof. 
   
   
       30 . The method of  claim 29 , wherein said administering to a patient in need thereof comprises administering for the purpose of the prophylaxis and/or treatment of disorders or diseases related to food intake, preferably for regulating appetite, for maintaining, increasing or reducing body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or diabetes type II, or for the prophylaxis and/or treatment of irritable bowel syndrome; disorders of the central nervous system, anxiety; panic attacks; depression; bipolar disorders; cognitive disorders; memory disorders; senile dementia; psychosis; schizophrenia; neurodegenerative disorders preferably selected between Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; or hyperactivity disorders, preferably attention deficit/hyperactivity disorder, or for improving cognitive capacity. 
   
   
       31 . Pharmaceutical composition comprising a compound according to any of  claims 1 - 4  and at least a pharmaceutically acceptable additive.